Cargando…

Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex

Previous results indicate that dopamine (DA) release in the medial prefrontal cortex (mPFC) is modified by α(2) adrenoceptor- but not D2 DA receptor- agonists and antagonists, suggesting that DA measured by microdialysis in the mPFC originates from noradrenergic terminals. Accordingly, noradrenergic...

Descripción completa

Detalles Bibliográficos
Autores principales: Devoto, Paola, Sagheddu, Claudia, Santoni, Michele, Flore, Giovanna, Saba, Pierluigi, Pistis, Marco, Gessa, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538903/
https://www.ncbi.nlm.nih.gov/pubmed/33071798
http://dx.doi.org/10.3389/fphar.2020.588160
_version_ 1783590955268440064
author Devoto, Paola
Sagheddu, Claudia
Santoni, Michele
Flore, Giovanna
Saba, Pierluigi
Pistis, Marco
Gessa, Gian Luigi
author_facet Devoto, Paola
Sagheddu, Claudia
Santoni, Michele
Flore, Giovanna
Saba, Pierluigi
Pistis, Marco
Gessa, Gian Luigi
author_sort Devoto, Paola
collection PubMed
description Previous results indicate that dopamine (DA) release in the medial prefrontal cortex (mPFC) is modified by α(2) adrenoceptor- but not D2 DA receptor- agonists and antagonists, suggesting that DA measured by microdialysis in the mPFC originates from noradrenergic terminals. Accordingly, noradrenergic denervation was found to prevent α(2)-receptor-mediated rise and fall of extracellular DA induced by atipamezole and clonidine, respectively, in the mPFC. The present study was aimed to determine whether DA released by dopaminergic terminals in the mPFC is not detected by in vivo microdialysis because is readily taken up by norepinephrine transporter (NET). Accordingly, the D2-antagonist raclopride increased the electrical activity of DA neurons in the ventral tegmental area (VTA) and enhanced extracellular DOPAC but failed to modify DA in the mPFC. However, in rats whose NET was either inactivated by nisoxetine or eliminated by noradrenergic denervation, raclopride still elevated extracellular DOPAC and activated dopaminergic activity, but also increased DA. Conversely, the D2-receptor agonist quinpirole reduced DOPAC but failed to modify DA in the mPFC in control rats. However, in rats whose NET was eliminated by noradrenergic denervation or inhibited by locally perfused nisoxetine, quinpirole maintained its ability to reduce DOPAC but acquired that of reducing DA. Moreover, raclopride and quinpirole, when locally perfused into the mPFC of rats subjected to noradrenergic denervation, were able to increase and decrease, respectively, extracellular DA levels, while being ineffective in control rats. Transient inactivation of noradrenergic neurons by clonidine infusion into the locus coeruleus, a condition where NET is preserved, was found to reduce extracellular NE and DA in the mPFC, whereas noradrenergic denervation, a condition where NET is eliminated, almost totally depleted extracellular NE but increased DA. Both transient inactivation and denervation of noradrenergic neurons were found to reduce the number of spontaneously active DA neurons and their bursting activity in the VTA. The results indicate that DA released in the mPFC by dopaminergic terminals is not detected by microdialysis unless DA clearance from extracellular space is inactivated. They support the hypothesis that noradrenergic terminals are the main source of DA measured by microdialysis in the mPFC during physiologically relevant activities.
format Online
Article
Text
id pubmed-7538903
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75389032020-10-15 Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex Devoto, Paola Sagheddu, Claudia Santoni, Michele Flore, Giovanna Saba, Pierluigi Pistis, Marco Gessa, Gian Luigi Front Pharmacol Pharmacology Previous results indicate that dopamine (DA) release in the medial prefrontal cortex (mPFC) is modified by α(2) adrenoceptor- but not D2 DA receptor- agonists and antagonists, suggesting that DA measured by microdialysis in the mPFC originates from noradrenergic terminals. Accordingly, noradrenergic denervation was found to prevent α(2)-receptor-mediated rise and fall of extracellular DA induced by atipamezole and clonidine, respectively, in the mPFC. The present study was aimed to determine whether DA released by dopaminergic terminals in the mPFC is not detected by in vivo microdialysis because is readily taken up by norepinephrine transporter (NET). Accordingly, the D2-antagonist raclopride increased the electrical activity of DA neurons in the ventral tegmental area (VTA) and enhanced extracellular DOPAC but failed to modify DA in the mPFC. However, in rats whose NET was either inactivated by nisoxetine or eliminated by noradrenergic denervation, raclopride still elevated extracellular DOPAC and activated dopaminergic activity, but also increased DA. Conversely, the D2-receptor agonist quinpirole reduced DOPAC but failed to modify DA in the mPFC in control rats. However, in rats whose NET was eliminated by noradrenergic denervation or inhibited by locally perfused nisoxetine, quinpirole maintained its ability to reduce DOPAC but acquired that of reducing DA. Moreover, raclopride and quinpirole, when locally perfused into the mPFC of rats subjected to noradrenergic denervation, were able to increase and decrease, respectively, extracellular DA levels, while being ineffective in control rats. Transient inactivation of noradrenergic neurons by clonidine infusion into the locus coeruleus, a condition where NET is preserved, was found to reduce extracellular NE and DA in the mPFC, whereas noradrenergic denervation, a condition where NET is eliminated, almost totally depleted extracellular NE but increased DA. Both transient inactivation and denervation of noradrenergic neurons were found to reduce the number of spontaneously active DA neurons and their bursting activity in the VTA. The results indicate that DA released in the mPFC by dopaminergic terminals is not detected by microdialysis unless DA clearance from extracellular space is inactivated. They support the hypothesis that noradrenergic terminals are the main source of DA measured by microdialysis in the mPFC during physiologically relevant activities. Frontiers Media S.A. 2020-09-23 /pmc/articles/PMC7538903/ /pubmed/33071798 http://dx.doi.org/10.3389/fphar.2020.588160 Text en Copyright © 2020 Devoto, Sagheddu, Santoni, Flore, Saba, Pistis and Gessa http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Devoto, Paola
Sagheddu, Claudia
Santoni, Michele
Flore, Giovanna
Saba, Pierluigi
Pistis, Marco
Gessa, Gian Luigi
Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title_full Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title_fullStr Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title_full_unstemmed Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title_short Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
title_sort noradrenergic source of dopamine assessed by microdialysis in the medial prefrontal cortex
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538903/
https://www.ncbi.nlm.nih.gov/pubmed/33071798
http://dx.doi.org/10.3389/fphar.2020.588160
work_keys_str_mv AT devotopaola noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT saghedduclaudia noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT santonimichele noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT floregiovanna noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT sabapierluigi noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT pistismarco noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex
AT gessagianluigi noradrenergicsourceofdopamineassessedbymicrodialysisinthemedialprefrontalcortex